Natural Product (NP) Details
| General Information of the NP (ID: NP4837) | |||||
|---|---|---|---|---|---|
| Name |
Costunolide
|
||||
| Synonyms |
Costunolide; 553-21-9; (+)-costunolide; Costunlide; Costundide; Costunolid; Costus lactone; CHEMBL86416; CHEBI:3900; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2(3H)-one; (E,E)-6-alpha-Hydroxygermacra-1(10),4,11(13)-trien-12-oic acid gamma-lactone; (10S,1R)-3,7-dimethyl-11-methylene-13-oxabicyclo[8.3.0]trideca-2,6-dien-12-one; (E,E)-germacra-1(10),4,11(13)-trien-12-oic acid, 6-alpha-hydroxy-gamma-lactone; (3aS,6E,10E)-3-Methylene-6,10-dimethyl-2,3,3abeta,4,5,8,9,11aalpha-octahydrocyclodeca[b]furan-2-one; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2(3H)-one; melampolide; NSC106404; Costunolide,(S); PubChem6258; SCHEMBL92714; Costunolide, >=97% (HPLC); HMS3269I17; HMS3413B19; HMS3677B19; HY-N0036; BDBM50411242; MFCD00210262; ZINC30726859; AKOS015840065; AKOS015969714; CS-1487; MCULE-2058016705; NCGC00381718-02; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylidene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one; AC-28334; AS-17708; V1471; C09382; 553C219; Q5175227; BRD-K26833429-001-01-0; (3aS,6E,10E,11aR)-3a,4,5,8,9,11a-Hexahydro-6,10-dimethyl-3-methylene-cyclodeca[b]furan-2(3H)-one; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylene-3,3a,4,5,8,9-hexahydrocyclodeca[b]furan-2(11aH)-one; (3aS,6E,10E,11aR)-6,10-dimethyl-3-methylene-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-2-one; Cyclodeca[b]furan-2(3H)-one, 3a,4,5,8,9,11a-hexahydro-6,10-dimethyl-3-methylene-, (3aS,6E,10E,11aR)-; NCGC00381718-02_C15H20O2_Cyclodeca[b]furan-2(3H)-one, 3a,4,5,8,9,11a-hexahydro-6,10-dimethyl-3-methylene-, (3aS,6E,10E,11aR)-
Click to Show/Hide
|
||||
| Species Origin | Magnolia sieboldii ... | Click to Show/Hide | |||
| Magnolia sieboldii | |||||
| Disease | Stomach cancer [ICD-11: 2B72] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-4.774
MDCK Permeability
-4.616
PAMPA
- - -
HIA
- -
Distribution
VDss
0.098
PPB
96%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+
CYP1A2 substrate
- -
CYP2C19 inhibitor
- -
CYP2C19 substrate
+
CYP2C9 inhibitor
- - -
CYP2C9 substrate
++
CYP2D6 inhibitor
- - -
CYP2D6 substrate
+
CYP3A4 inhibitor
- -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
+++
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
++
Excretion
CLplasma
9.487
T1/2
1.836
Toxicity
DILI
+++
Rat Oral Acute Toxicity
- -
FDAMDD
-
Respiratory
- -
Human Hepatotoxicity
++
Ototoxicity
- -
Drug-induced Nephrotoxicity
++
Drug-induced Neurotoxicity
++
Hematotoxicity
+
Genotoxicity
-
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C15H20O2
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1=CCCC(=CC2C(CC1)C(=C)C(=O)O2)C
|
||||
| InChI |
1S/C15H20O2/c1-10-5-4-6-11(2)9-14-13(8-7-10)12(3)15(16)17-14/h5,9,13-14H,3-4,6-8H2,1-2H3/b10-5+,11-9+/t13-,14+/m0/s1
|
||||
| InChIKey |
HRYLQFBHBWLLLL-AHNJNIBGSA-N
|
||||
| CAS Number |
CAS 553-21-9
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| TTD Drug ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Imatinib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway. | |||||
| Ionizing radiation | Renal Insufficiency | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [3] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Phosphorylation | CDK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | MPIP3 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | RAD53 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | HA22T/VGH | CVCL_7046 | Adult hepatocellular carcinoma | Homo sapiens | ||
| Experimental
Result(s) |
Costunolide causes mitotic arrest and enhances radiosensitivity in human hepatocellular carcinoma cells. | |||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [4] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Phosphorylation | AKT1 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | PIK3CB | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | ||
| Experimental
Result(s) |
Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Microtubule-associated protein (MAP) | Molecule Info | [5] | |